FOLLICULAR LYMPHOMA
Clinical trials for FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug cocktail targets untreated follicular lymphoma
Disease control Not yet recruitingThis study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. About 27 newly diagnosed adults will receive the drugs to see how well they shrink tumors and contro…
Matched conditions: FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 07:05 UTC
-
Immune cell army targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) to help the body fight the…
Matched conditions: FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New shot could fight lymphoma without chemo
Disease control Not yet recruitingThis study tests a drug called mosunetuzumab, given as a shot under the skin, for people with a slow-growing blood cancer called follicular lymphoma that hasn't been treated yet. The goal is to see if it can shrink tumors and control the disease without needing chemotherapy. Abou…
Matched conditions: FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Promising combo targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. Participants include those with newly diagnosed high-risk or low-tumor-burden disease, as well as those whose cancer has returned or …
Matched conditions: FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug trial offers hope for Tough-to-Treat lymphoma
Disease control Not yet recruitingThis study is testing a new injection called TQB2825 against standard immunotherapy for people with follicular lymphoma that has returned or hasn't responded to previous treatments. The main goal is to see which treatment keeps the cancer from getting worse for a longer time. Res…
Matched conditions: FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New study aims to make allergy testing safer for cancer patients on biologics
Knowledge-focused Not yet recruitingThis study involves 70 patients with various cancers who are receiving biotherapy drugs. Researchers want to find the highest safe concentration of these drugs to use in skin allergy tests, so they can better diagnose allergic reactions. The goal is to create clear guidelines for…
Matched conditions: FOLLICULAR LYMPHOMA
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC